

# Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Ant

New England Journal of Medicine

368, 218-230

DOI: [10.1056/nejmoa1110187](https://doi.org/10.1056/nejmoa1110187)

Citation Report

#	ARTICLE	IF	CITATIONS
2	A novel acute HIV infection staging system based on 4th generation immunoassay. <i>Retrovirology</i> , 2013, 10, 56.	0.9	93
3	When to start antiretroviral therapy: the need for an evidence base during early HIV infection. <i>BMC Medicine</i> , 2013, 11, 148.	2.3	30
5	Dynamics of Viral Evolution and Neutralizing Antibody Response after HIV-1 Superinfection. <i>Journal of Virology</i> , 2013, 87, 12737-12744.	1.5	22
7	Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. <i>Immunological Reviews</i> , 2013, 254, 343-354.	2.8	117
8	CD4 <sup>+</sup> T-cell depletion in HIV infection: mechanisms of immunological failure. <i>Immunological Reviews</i> , 2013, 254, 54-64.	2.8	412
9	Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. <i>Lancet</i> , 2013, 382, 1515-1524.	6.3	202
10	Antiretroviral Therapy in Early HIV Infection. <i>New England Journal of Medicine</i> , 2013, 368, 279-281.	13.9	22
11	Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort. <i>BMC Immunology</i> , 2013, 14, 26.	0.9	16
12	Immunology of pediatric HIV infection. <i>Immunological Reviews</i> , 2013, 254, 143-169.	2.8	97
13	Real-world impact of neurocognitive deficits in acute and early HIV infection. <i>Journal of NeuroVirology</i> , 2013, 19, 565-573.	1.0	43
14	The Detection and Management of Early HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S187-S199.	0.9	50
15	Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. <i>BMJ Open</i> , 2013, 3, e003499.	0.8	83
16	When to start ART in Africa – primarily guided by RCTs or patient autonomy?. <i>Journal of the International AIDS Society</i> , 2013, 16, 18756.	1.2	2
17	Clinical trials provide the evidence critical for patient empowerment. <i>Journal of the International AIDS Society</i> , 2013, 16, 18811.	1.2	0
18	Editorial Commentary: Balancing Disease Eradication With the Emergence of Multidrug-Resistant HIV in Test-and-Treat Policies. <i>Clinical Infectious Diseases</i> , 2013, 56, 1797-1799.	2.9	3
19	The natural history of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	1.5	50
20	Robust suppression of SHIV viremia in M <sub>1</sub> acaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection. <i>Journal of Medical Primatology</i> , 2013, 42, 237-246.	0.3	14
21	Acute HIV-1 Infection: A Call to Action. <i>Annals of Internal Medicine</i> , 2013, 159, 425.	2.0	3

#	ARTICLE	IF	CITATIONS
22	Challenges in identifying and estimating undiagnosed HIV infection. <i>Future Virology</i> , 2013, 8, 523-526.	0.9	2
24	ART sooner rather than later for adults with HIV. <i>BMJ, The</i> , 2013, 346, f377-f377.	3.0	0
25	Multi-Centre Evaluation of the Determine HIV Combo Assay when Used for Point of Care Testing in a High Risk Clinic-Based Population. <i>PLoS ONE</i> , 2014, 9, e94062.	1.1	41
26	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. <i>PLoS ONE</i> , 2014, 9, e114111.	1.1	17
27	Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. <i>Journal of the International AIDS Society</i> , 2014, 17, 19480.	1.2	37
29	Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum. <i>Journal of NeuroVirology</i> , 2014, 20, 514-520.	1.0	15
30	Activities of Transmitted/Founder and Chronic Clade B HIV-1 Vpu and a C-Terminal Polymorphism Specifically Affecting Virion Release. <i>Journal of Virology</i> , 2014, 88, 5062-5078.	1.5	26
31	Significant publications on infectious diseases pharmacotherapy in 2013. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1974-1988.	0.5	10
32	Human APOBEC3 Induced Mutation of Human Immunodeficiency Virus Type-1 Contributes to Adaptation and Evolution in Natural Infection. <i>PLoS Pathogens</i> , 2014, 10, e1004281.	2.1	83
33	Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. <i>Aids</i> , 2014, 28, 841-849.	1.0	11
34	Community HIV drug resistance is associated with transmitted drug resistance. <i>HIV Medicine</i> , 2014, 15, 339-346.	1.0	11
35	Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort. <i>Immunology Letters</i> , 2014, 162, 264-272.	1.1	11
36	The changing face of the HIV epidemic in sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2014, 19, 1015-1028.	1.0	31
37	Late presentation to HIV/AIDS testing, treatment or continued care: clarifying the use of CD4 evaluation in the consensus definition. <i>HIV Medicine</i> , 2014, 15, 130-134.	1.0	15
38	HIV. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 545-553.	1.3	17
39	Can early therapy reduce inflammation?. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 72-79.	1.5	41
40	HIV Prevention in Clinical Care Settings. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 390.	3.8	109
41	HIV-1 testing of young febrile adults seeking care for fever in sub-Saharan Africa. <i>International Health</i> , 2014, 6, 77-78.	0.8	1

#	ARTICLE	IF	CITATIONS
42	Update on antiretroviral treatment during primary HIV infection. Expert Review of Anti-Infective Therapy, 2014, 12, 793-807.	2.0	23
43	Acute HIV-1 infection in sub-Saharan Africa. Aids, 2014, 28, 1365-1367.	1.0	18
44	The dermatologist and the HIV/AIDS pandemic. Clinics in Dermatology, 2014, 32, 286-289.	0.8	10
45	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infectious Diseases, The, 2014, 14, 281-290.	4.6	423
46	Early Treatment during Primary Infection Holds the Key to a Functional Cure for HIV. Intervirology, 2014, 57, 52-53.	1.2	1
47	Incidence and Prevalence of Intrasubtype HIV-1 Dual Infection in At-Risk Men in the United States. Journal of Infectious Diseases, 2014, 209, 1032-1038.	1.9	42
48	A case cluster demonstrating the relationship between HLA concordance and virologic and disease outcomes in human immunodeficiency virus infection. Virology, 2014, 449, 104-108.	1.1	1
49	Using CD4 Percentage and Age to Optimize Pediatric Antiretroviral Therapy Initiation. Pediatrics, 2014, 134, e1104-e1116.	1.0	16
50	HIV-1 and HIV-2 Differentially Mature Plasmacytoid Dendritic Cells into IFN-Producing Cells or APCs. Journal of Immunology, 2014, 193, 3538-3548.	0.4	14
51	Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. Journal of Virology, 2014, 88, 10056-10065.	1.5	242
52	HIV and Stem Cell Transplantation. Current Infectious Disease Reports, 2014, 16, 424.	1.3	6
53	Stem memory T cells (TSCM) – their role in cancer and HIV immunotherapies. Clinical and Translational Immunology, 2014, 3, e20.	1.7	68
54	Sida: conceptos inmunológicos y clínicos básicos. FMC Formacion Medica Continuada En Atencion Primaria, 2014, 21, 325-335.	0.0	0
56	Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clinical and Experimental Immunology, 2014, 176, 401-409.	1.1	27
57	Antiretroviral Therapy. Infectious Disease Clinics of North America, 2014, 28, 403-420.	1.9	7
58	The HIV Epidemic in Southern Africa – Is an AIDS-Free Generation Possible?. Current HIV/AIDS Reports, 2014, 11, 99-108.	1.1	21
59	Determinants of HIV-induced brain changes in three different periods of the early clinical course: A data mining analysis. NeuroImage: Clinical, 2015, 9, 75-82.	1.4	16
60	Evolving Human Rights and the Science of Antiretroviral Medicine. Health and Human Rights, 2015, 17, 76.	1.3	9

#	ARTICLE	IF	CITATIONS
61	Barriers to HIV testing and characteristics associated with never testing among gay and bisexual men attending sexual health clinics in Sydney. <i>Journal of the International AIDS Society</i> , 2015, 18, 20221.	1.2	54
62	HIV Transmission Networks in the San Diego–Tijuana Border Region. <i>EBioMedicine</i> , 2015, 2, 1456-1463.	2.7	51
63	Australian health care providers'™ views on opt-out HIV testing. <i>BMC Public Health</i> , 2015, 15, 888.	1.2	4
64	Repeat HIV-testing is associated with an increase in behavioral risk among men who have sex with men: a cohort study. <i>BMC Medicine</i> , 2015, 13, 218.	2.3	46
65	Impaired Th17 polarization of phenotypically naive CD4+ T-cells during chronic HIV-1 infection and potential restoration with early ART. <i>Retrovirology</i> , 2015, 12, 38.	0.9	30
66	Risk Factors for Acute and Early HIV Infection Among Men Who Have Sex With Men (MSM) in San Diego, 2008 to 2014. <i>Medicine (United States)</i> , 2015, 94, e1242.	0.4	27
67	No evidence of posttreatment control after early initiation of antiretroviral therapy. <i>Aids</i> , 2015, 29, 2093-2097.	1.0	24
68	The HIV treatment cascade in acutely infected people. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 395-402.	1.5	12
69	The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels. <i>Aids</i> , 2015, 29, 1355-1361.	1.0	16
70	Strengthening healthcare providers'™ skills to improve HIV services for MSM in Kenya. <i>Aids</i> , 2015, 29, S237-S240.	1.0	23
71	What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan. <i>PLoS ONE</i> , 2015, 10, e0143874.	1.1	9
72	The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China. <i>BioScience Trends</i> , 2015, 9, 335-341.	1.1	16
73	Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 35-42.	1.5	60
74	Preserving HIV-specific T cell responses. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 55-60.	1.5	20
75	Development and Validation of the San Diego Early Test Score to Predict Acute and Early HIV Infection Risk in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 61, 468-475.	2.9	85
76	Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?. <i>BMC Infectious Diseases</i> , 2015, 15, 178.	1.3	1
77	Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus 1–Infected Individuals. <i>JAMA Internal Medicine</i> , 2015, 175, 88.	2.6	69
78	Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 1542-1547.	1.7	76

#	ARTICLE	IF	CITATIONS
79	Prise en charge de la primo-infection VIH-1. <i>Journal Des Anti-infectieux</i> , 2015, 17, 163-172.	0.1	0
80	Enrolment trends in a comprehensive HIV programme in rural north-central Nigeria: improved care indices, but declining quality of clinical data over time. <i>Pathogens and Global Health</i> , 2015, 109, 75-83.	1.0	3
81	Costs per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening Algorithms. <i>Clinical Infectious Diseases</i> , 2015, 62, civ912.	2.9	36
82	Adult HIV Infection Treatment Update 2014: An Approach to HIV Infection Management and Antiretroviral Treatment. <i>Journal for Nurse Practitioners</i> , 2015, 11, 95-102.	0.4	2
83	Brain alterations within the first 100 days of HIV infection. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 12-21.	1.7	85
84	Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. <i>Journal of Immunology</i> , 2015, 195, 2273-2281.	0.4	24
85	Knowledge and Awareness of Acute Human Immunodeficiency Virus Infection Among Mobile App-Using Men Who Have Sex With Men: A Missed Public Health Opportunity. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv016.	0.4	6
86	Significant ambivalence: perspectives of Australian HIV service providers on universal treatment-as-prevention (TasP) for serodiscordant couples. <i>Critical Public Health</i> , 2015, 25, 153-164.	1.4	10
87	Five-drug antiretroviral therapy for primary HIV infection?. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 362-363.	4.6	0
88	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2108-2120.	1.3	92
89	How can we better identify early HIV infections?. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 61-68.	1.5	55
91	Editorial Commentary: Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1196-1198.	2.9	3
92	Post-treatment control: a functional cure for HIV. <i>Future Virology</i> , 2015, 10, 1245-1256.	0.9	0
93	Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care. <i>International Journal of STD and AIDS</i> , 2015, 26, 951-959.	0.5	6
94	Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights from Southern California. <i>Annals of Epidemiology</i> , 2015, 25, 1-6.	0.9	20
95	HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing. <i>Virology</i> , 2015, 474, 34-40.	1.1	19
96	Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 111-119.	0.9	21
97	Characterizing the multiplicity of HIV founder variants during sexual transmission among MSM. <i>Virus Evolution</i> , 2016, 2, vew012.	2.2	14

#	ARTICLE	IF	CITATIONS
98	Signs or Symptoms of Acute HIV Infection in a Cohort Undergoing Community-Based Screening. <i>Emerging Infectious Diseases</i> , 2016, 22, 532-534.	2.0	45
99	The validity of the biological eligibility criteria to antiretroviral treatment in comparison to the systematic antiretroviral treatment in a cohort of people living with the HIV in the Southern Kivu Province, Democratic Republic of the Congo. <i>Pan African Medical Journal</i> , 2016, 25, 210.	0.3	2
100	Impact of early cART in the gut during acute HIV infection. <i>JCI Insight</i> , 2016, 1, .	2.3	56
101	Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. <i>Aids</i> , 2016, 30, 193-201.	1.0	38
102	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. <i>Aids</i> , 2016, 30, 879-888.	1.0	9
103	Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection. <i>Aids</i> , 2016, 30, 2117-2124.	1.0	46
104	When to consider acute HIV infection in the differential diagnosis. <i>Nurse Practitioner</i> , 2016, 41, 1-5.	0.2	2
105	On the Margins of Pharmaceutical Citizenship: Not Taking HIV Medication in the "Treatment Revolution" Era. <i>Medical Anthropology Quarterly</i> , 2016, 30, 359-377.	0.7	26
106	Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 69-73.	0.9	38
107	Virologic failure is uncommon after treatment initiation during acute HIV infection. <i>Aids</i> , 2016, 30, 1943-1950.	1.0	21
108	Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 228-236.	0.9	47
109	Primary HIV infection: a medical and public health emergency requiring rapid specialist management. <i>Clinical Medicine</i> , 2016, 16, 180-183.	0.8	4
110	CXCR4-using HIV variants in a cohort of Black men who have sex with men: HIV Prevention Trials Network 061. <i>HIV Clinical Trials</i> , 2016, 17, 158-164.	2.0	1
111	Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis. <i>Scientific Reports</i> , 2016, 6, 32947.	1.6	75
112	Longitudinal Viral Dynamics in Semen During Early HIV Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw784.	2.9	17
113	Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin. <i>BMC Infectious Diseases</i> , 2016, 16, 591.	1.3	6
114	Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 5-19.	6.6	26
115	Using HIV Sequence and Epidemiologic Data to Assess the Effect of Self-referral Testing for Acute HIV Infection on Incident Diagnoses in San Diego, California. <i>Clinical Infectious Diseases</i> , 2016, 63, 101-107.	2.9	20

#	ARTICLE	IF	CITATIONS
116	Optimal control therapy and vaccination for special HIV-1 model with delay. <i>Theory in Biosciences</i> , 2016, 135, 217-230.	0.6	4
117	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	1.0	78
118	How can we detect HIV during the acute or primary stage of infection?. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1049-1051.	1.5	1
119	Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up. <i>Journal of Clinical Virology</i> , 2016, 85, 86-89.	1.6	2
120	Factors Associated with Returning At-Home Specimen Collection Kits for HIV Testing among Internet-Using Men Who Have Sex with Men. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 463-469.	0.6	19
121	Asymptomatic CMV Replication During Early Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower CD4/CD8 Ratio During HIV Treatment. <i>Clinical Infectious Diseases</i> , 2016, 63, 1517-1524.	2.9	43
122	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2016, 375, 830-839.	13.9	1,282
123	Routine Screening for HIV Infection in Medical Care Settings: A Decade of Progress and Next Opportunities. <i>Public Health Reports</i> , 2016, 131, 1-4.	1.3	17
124	A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics. <i>Scientific Reports</i> , 2016, 6, 28707.	1.6	6
125	Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients. <i>BMC Medical Research Methodology</i> , 2016, 16, 121.	1.4	5
126	A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics. <i>Medicine (United States)</i> , 2016, 95, e5315.	0.4	4
127	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016, 95, e5094.	0.4	22
128	Concurrency and HIV transmission network characteristics among MSM with recent HIV infection. <i>Aids</i> , 2016, 30, 2875-2883.	1.0	35
129	Immune recovery in HIV-infected patients after <i>Candida</i> esophagitis is impaired despite long-term antiretroviral therapy. <i>Aids</i> , 2016, 30, 1923-1933.	1.0	6
130	Neurobehavioral Disturbances During Acute and Early HIV Infection. <i>Cognitive and Behavioral Neurology</i> , 2016, 29, 1-10.	0.5	24
131	Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. <i>Infectious Diseases and Therapy</i> , 2016, 5, 65-71.	1.8	19
132	Timing of antiretroviral therapy initiation after diagnosis of recent human immunodeficiency virus infection and CD4+ T-cell recovery. <i>Clinical Microbiology and Infection</i> , 2016, 22, 290.e5-290.e8.	2.8	9
133	Colorectal Disorders in Acute Human Immunodeficiency Virus Infection: A Case Series. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw014.	0.4	1



#	ARTICLE	IF	CITATIONS
134	Let's treat everyone with HIV now: what happens next?. <i>Lancet HIV</i> , 2016, 3, e109-e110.	2.1	0
135	T cell and reticular network co-dependence in HIV infection. <i>Journal of Theoretical Biology</i> , 2016, 395, 211-220.	0.8	14
136	Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. <i>Journal of Virology</i> , 2016, 90, 3944-3952.	1.5	52
137	Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 106-114.	2.9	11
138	Diagnosing acute HIV infection at point of care: a retrospective analysis of the sensitivity and specificity of a fourth-generation point-of-care test for detection of HIV core protein p24. <i>Sexually Transmitted Infections</i> , 2017, 93, 100-101.	0.8	28
139	Barriers to Universal Prescribing of Antiretroviral Therapy by HIV Care Providers in the United States, 2013-2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 479-487.	0.9	16
140	Real-world performance of the new US HIV testing algorithm in medical settings. <i>Journal of Clinical Virology</i> , 2017, 91, 73-78.	1.6	11
141	Interaction Effects between HIV and Aging on Selective Neurocognitive Impairment. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 661-669.	2.1	24
142	Development and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with men. <i>BMC Infectious Diseases</i> , 2017, 17, 425.	1.3	21
143	Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response. <i>Journal of Virology</i> , 2017, 91, .	1.5	10
144	HIV Trafficking Between Blood and Semen During Early Untreated HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 95-102.	0.9	19
145	Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e114-e117.	0.9	5
146	Barriers and facilitators to HIV testing among young men who have sex with men and transgender women in Kingston, Jamaica: a qualitative study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21385.	1.2	78
147	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. <i>Journal of the International AIDS Society</i> , 2017, 20, 21579.	1.2	107
148	Primary HIV Infection: Clinical Presentation, Testing, and Treatment. <i>Current Infectious Disease Reports</i> , 2017, 19, 37.	1.3	20
149	Sexual Partner Concurrency Among Partners Reported by MSM with Recent HIV Infection. <i>AIDS and Behavior</i> , 2017, 21, 3026-3034.	1.4	18
150	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 126-133.	0.9	32
151	Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. <i>Aids</i> , 2017, 31, 477-484.	1.0	51

#	ARTICLE	IF	CITATIONS
152	Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. <i>Journal of Medical Ethics</i> , 2018, 44, medethics-2017-104433.	1.0	51
153	The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy. <i>Medicine (United States)</i> , 2017, 96, e7430.	0.4	8
154	Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles. <i>Aids</i> , 2017, 31, 1149-1158.	1.0	6
155	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 632-633.	1.3	9
156	A comprehensive theoretical framework for the implementation and evaluation of opt-out HIV testing. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 301-307.	0.9	4
157	Reference curves for CD4 cell count response to combination antiretroviral therapy in HIV-1 infected treatment-naïve patients. <i>HIV Medicine</i> , 2017, 18, 33-44.	1.0	16
158	Prevalence and Risk Factors of Mortality among Adult HIV Patients Initiating ART in Rural Setting of HIV Care and Treatment Services in North Western Tanzania: A Retrospective Cohort Study. <i>Journal of Sexually Transmitted Diseases</i> , 2017, 2017, 1-8.	1.0	19
159	Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand. <i>Journal of the International AIDS Society</i> , 2017, 20, 21652.	1.2	16
160	Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2018, 67, 927-933.	2.9	34
161	Insight on the regulation of chemokine activities. <i>Journal of Leukocyte Biology</i> , 2018, 104, 295-300.	1.5	6
162	Alteration of CCR6 + CD95 + CD4 + naïve T cells in HIV-1 infected patients: Implication for clinical practice. <i>Cellular Immunology</i> , 2018, 327, 47-53.	1.4	1
163	Care continuum entry interventions. <i>Aids</i> , 2018, 32, 407-417.	1.0	14
164	Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial. <i>AIDS and Behavior</i> , 2018, 22, 2277-2283.	1.4	3
165	Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. <i>Aids</i> , 2018, 32, 443-450.	1.0	35
166	Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 1519-1527.	2.9	25
167	Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells. <i>AIDS Research and Therapy</i> , 2018, 15, 7.	0.7	35
168	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. <i>Clinical Microbiology and Infection</i> , 2018, 24, 540-545.	2.8	13
169	Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. <i>HIV Medicine</i> , 2018, 19, 184-194.	1.0	41

#	ARTICLE	IF	CITATIONS
170	Lymphocyte-Dominant Encephalitis and Meningitis in Simian Immunodeficiency Virus-Infected Macaques Receiving Antiretroviral Therapy. <i>American Journal of Pathology</i> , 2018, 188, 125-134.	1.9	8
171	Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. <i>Journal of Virology</i> , 2018, 92, .	1.5	17
172	The contribution of observational studies in supporting the WHO "treat all" recommendation for HIV/AIDS. <i>Journal of Virus Eradication</i> , 2018, 4, 5-8.	0.3	13
173	The early bird gets the worm: benefits and future directions with early antiretroviral therapy initiation in primary HIV infection. <i>Future Virology</i> , 2018, 13, 779-786.	0.9	10
174	Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 510-518.	0.9	29
176	No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 657-666.	0.5	11
177	Induction of a Na <sup>+</sup> /K <sup>+</sup> -ATPase-dependent form of autophagy triggers preferential cell death of human immunodeficiency virus type-1-infected macrophages. <i>Autophagy</i> , 2018, 14, 1359-1375.	4.3	26
178	Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy. <i>Frontiers in Public Health</i> , 2018, 6, 70.	1.3	8
179	Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa. <i>PLoS ONE</i> , 2018, 13, e0192785.	1.1	4
180	Sustained Sexual Behavior Change After Acute HIV Diagnosis in Malawi. <i>Sexually Transmitted Diseases</i> , 2018, 45, 741-746.	0.8	10
181	HIV DNA Measurement and Improved Detection of HIV Infection Among Men Who Have Sex with Men: A Strategic Implication. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 920-923.	0.5	1
182	Genetic and clinical predictors of CD4 lymphocyte recovery during suppressive antiretroviral therapy: Whole exome sequencing and antiretroviral therapy response phenotypes. <i>PLoS ONE</i> , 2019, 14, e0219201.	1.1	8
183	Advanced HIV Disease among Males and Females Initiating HIV Care in Rural Ethiopia. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821984719.	0.6	13
184	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. <i>Viruses</i> , 2019, 11, 607.	1.5	12
185	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EClinicalMedicine</i> , 2019, 11, 65-80.	3.2	52
186	Why Everyone (Almost) with HIV Needs to Be on Treatment. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 663-679.	1.9	8
187	Two types of poor immunological responder showing distinct responses to long-term HAART. <i>International Journal of Infectious Diseases</i> , 2019, 86, 178-187.	1.5	5
188	Intention to initiate antiretroviral therapy (ART) among people living with HIV in China under the scaling-up of ART: the role of healthcare workers' recommendations. <i>BMC Health Services Research</i> , 2019, 19, 314.	0.9	6

#	ARTICLE	IF	CITATIONS
189	Association of Cytomegalovirus DNA and Immunologic Markers of Cardiovascular Disease. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz113.	0.4	6
190	Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection. <i>EBioMedicine</i> , 2019, 43, 307-316.	2.7	61
191	Health outcomes of asymptomatic HIV-infected pregnant women initiating antiretroviral therapy at different baseline CD4 counts in Ethiopia. <i>International Journal of Infectious Diseases</i> , 2019, 82, 89-95.	1.5	5
192	Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. <i>HIV Medicine</i> , 2019, 20, 3-11.	1.0	68
193	The dynamic association between Frailty, CD4 and CD4/CD8 ratio in people aging with HIV. <i>PLoS ONE</i> , 2019, 14, e0212283.	1.1	24
194	The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection. <i>Aids</i> , 2019, 33, 1335-1344.	1.0	16
195	Integrase strand-transfer inhibitors for treatment of early HIV infection. <i>Medicine (United States)</i> , 2019, 98, e16866.	0.4	0
196	Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. <i>Journal of the International AIDS Society</i> , 2019, 22, e25419.	1.2	49
197	Is reaching 90% enough to end AIDS? Lessons from Amsterdam. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 455-463.	1.5	10
198	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm <sup>3</sup> : Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 10-17.	0.9	13
199	Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1129-1143.	1.3	16
200	Daily Nutritional Supplementation with Vitamin D3 and Phenylbutyrate to Treatment-Naïve HIV Patients Tested in a Randomized Placebo-Controlled Trial. <i>Nutrients</i> , 2019, 11, 133.	1.7	11
201	Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 480-488.	1.3	1
202	Effect of Cannabis Use on Human Immunodeficiency Virus DNA During Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2020, 70, 140-143.	2.9	21
203	Genetic Network Analysis to Assess the Risk of Human Immunodeficiency Virus Transmission Among Men Who Have Sex With Men Seeking Partners on the Internet. <i>Clinical Infectious Diseases</i> , 2020, 70, 925-932.	2.9	6
204	Compromised CD4:CD8 ratio recovery in people living with HIV aged over 50 years: an observational study. <i>HIV Medicine</i> , 2020, 21, 109-118.	1.0	6
205	Impact of Early Antiretroviral Therapy Initiation on HIV-Specific CD4 and CD8 T Cell Function in Perinatally Infected Children. <i>Journal of Immunology</i> , 2020, 204, 540-549.	0.4	20
206	Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection. <i>Aids</i> , 2020, 34, 415-426.	1.0	21

#	ARTICLE	IF	CITATIONS
207	Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection. <i>Aids</i> , 2020, 34, 493-500.	1.0	10
208	Validation of the BD FACSPresto system for the measurement of CD4 T-lymphocytes and hemoglobin concentration in HIV-negative and HIV-positive subjects. <i>Scientific Reports</i> , 2020, 10, 19605.	1.6	4
209	Rapid Antiretroviral Therapy Among Individuals With Acute and Early HIV. <i>Clinical Infectious Diseases</i> , 2021, 73, 130-133.	2.9	18
210	Unique Needs for the Implementation of Emergency Department Human Immunodeficiency Virus Screening in Adolescents. <i>Academic Emergency Medicine</i> , 2020, 27, 984-994.	0.8	3
211	Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia. <i>PLoS ONE</i> , 2020, 15, e0240880.	1.1	10
212	Determinants of suboptimal CD4 + T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection. <i>Journal of the International AIDS Society</i> , 2020, 23, e25585.	1.2	13
213	Asymptomatic Adolescent HIV: Identifying a Role for Universal HIV Screening in the Pediatric Emergency Department. <i>AIDS Patient Care and STDs</i> , 2020, 34, 373-379.	1.1	13
214	Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection. <i>Aids</i> , 2020, 34, 2269-2274.	1.0	8
215	Effects of Early and Delayed Antiretroviral Therapy on Plasma Anti-CD4 Autoreactive IgG and Its Association With CD4+ T-Cell Recovery in Acute HIV-Infected Individuals. <i>Frontiers in Pharmacology</i> , 2020, 11, 449.	1.6	11
216	Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV-1 infection: results from a longitudinal study in the French ANRS Primo cohort. <i>Journal of the International AIDS Society</i> , 2020, 23, e25485.	1.2	10
217	Comparative multi-assay evaluation of Determine <sup>®</sup> , <sup>®</sup> HIV-1/2 Ag/Ab Combo rapid diagnostic tests in acute and chronic HIV infection. <i>Medical Microbiology and Immunology</i> , 2020, 209, 139-150.	2.6	9
218	The management of treatment-experienced HIV patients (including virologic failure and switches). <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612090139.	1.1	12
219	Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The <i>SABES</i> Randomized Clinical Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1042-1050.	2.9	15
220	Effective Human Immunodeficiency Virus Molecular Surveillance Requires Identification of Incident Cases of Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, 842-849.	2.9	9
221	Stem cell-like memory T cells: A perspective from the dark side. <i>Cellular Immunology</i> , 2021, 361, 104273.	1.4	13
222	Atazanavir/ritonavir vs Efavirenz como primeira linha de tratamento em adultos vivendo com HIV. , 2021, 100, 28-34.	0.0	0
223	Recent HIV infection among pregnant women in the 2017 antenatal sentinel cross-sectional survey, South Africa: Assay-based incidence measurement. <i>PLoS ONE</i> , 2021, 16, e0249953.	1.1	24
224	Exceptional T CD4 <sup>+</sup> Recovery Post-antiretroviral Is Linked to a Lower HIV Reservoir with a Specific Immune Differentiation Pattern. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 11-21.	0.5	2

#	ARTICLE	IF	CITATIONS
225	Immunological and Virological Failure among Individuals on Highly-Active Antiretroviral Therapy. , 0, , .		0
226	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. PLoS Pathogens, 2021, 17, e1009785.	2.1	12
227	Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection. Frontiers in Immunology, 2021, 12, 738743.	2.2	7
228	Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in Eswatini. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 506-517.	0.9	5
229	Immunologic resilience and COVID-19 survival advantage. Journal of Allergy and Clinical Immunology, 2021, 148, 1176-1191.	1.5	21
230	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	2.1	25
231	Revolution or Evolution? What Can Approaches Based on the Use of Antiretroviral Drugs Contribute to HIV Prevention in Gay Communities in High-Income Countries?. , 2014, , 181-204.		3
232	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. Journal of Infectious Diseases, 2021, 224, 657-666.	1.9	3
233	Integrase Strand Transfer Inhibitors Play the Main Role in Greater Weight Gain Among Men With Acute and Early HIV Infection. Open Forum Infectious Diseases, 2021, 8, ofaa619.	0.4	9
234	Rapid Sequencing of Complete <i>env</i> Genes from Primary HIV-1 Samples. Virus Evolution, 2016, 2, vew018.	2.2	30
235	The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2. Current Opinion in HIV and AIDS, 2021, 16, 36-47.	1.5	6
236	Never too early for the opportunists!. BMJ Case Reports, 2013, 2013, bcr2013009612-bcr2013009612.	0.2	2
237	Performance of Rapid Point-of-Care and Laboratory Tests for Acute and Established HIV Infection in San Francisco. PLoS ONE, 2013, 8, e80629.	1.1	57
238	Using HIV Networks to Inform Real Time Prevention Interventions. PLoS ONE, 2014, 9, e98443.	1.1	158
239	Generation of a Recombinant Gag Virus-Like-Particle Panel for the Evaluation of p24 Antigen Detection by Diagnostic HIV Tests. PLoS ONE, 2014, 9, e111552.	1.1	11
240	Rapid HIV Testing Is Highly Acceptable and Preferred among High-Risk Gay And Bisexual Men after Implementation in Sydney Sexual Health Clinics. PLoS ONE, 2015, 10, e0123814.	1.1	25
241	Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria. PLoS ONE, 2015, 10, e0125665.	1.1	4
242	Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. PLoS ONE, 2015, 10, e0131651.	1.1	5

#	ARTICLE	IF	CITATIONS
243	Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells. <i>PLoS ONE</i> , 2015, 10, e0139573.	1.1	15
244	CD4 Counts at Entry to HIV Care in Mexico for Patients under the "Universal Antiretroviral Treatment Program for the Uninsured Population," 2007-2014. <i>PLoS ONE</i> , 2016, 11, e0152444.	1.1	9
245	Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. <i>PLoS ONE</i> , 2016, 11, e0152910.	1.1	30
246	Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database. <i>PLoS ONE</i> , 2016, 11, e0164148.	1.1	18
247	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , 2017, 12, e0189045.	1.1	4
248	P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART. <i>PLoS Pathogens</i> , 2016, 12, e1005571.	2.1	22
249	Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations. <i>PLoS Pathogens</i> , 2017, 13, e1006112.	2.1	52
250	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16
251	mHealth Interventions to Promote Anti-Retroviral Adherence in HIV: Narrative Review. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14739.	1.8	23
252	Mixed method approach for determining factors associated with late presentation to HIV/AIDS care in southern India. <i>Journal of Postgraduate Medicine</i> , 2016, 62, 173-177.	0.2	5
254	STUDY OF CD4 COUNT IN HIV PATIENTS ON HAART THERAPY. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2016, 5, 7034-7041.	0.1	0
255	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
257	Bayesian reconstruction of transmission trees from genetic sequences and uncertain infection times. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2020, 19, .	0.2	3
258	Treatment of Acute HIV Infection and the Potential Role of Acutely HIV-Infected Persons in Cure Studies. <i>Topics in Antiviral Medicine</i> , 2016, 23, 156-60.	0.1	2
259	The contribution of observational studies in supporting the WHO 'treat all' recommendation for HIV/AIDS. <i>Journal of Virus Eradication</i> , 2018, 4, 5-8.	0.3	13
260	Plasma MicroRNA Signature Panel Predicts the Immune Response After Antiretroviral Therapy in HIV-Infected Patients. <i>Frontiers in Immunology</i> , 2021, 12, 753044.	2.2	6
261	Baseline Characteristics of Mitochondrial DNA and Mutations Associated With Short-Term Posttreatment CD4+T-Cell Recovery in Chinese People With HIV. <i>Frontiers in Immunology</i> , 2021, 12, 793375.	2.2	0
262	Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients. <i>Cells</i> , 2022, 11, 208.	1.8	0

#	ARTICLE	IF	CITATIONS
264	Determinants of suboptimal immune recovery among a Chinese Yi ethnicity population with sustained HIV suppression. <i>BMC Infectious Diseases</i> , 2022, 22, 137.	1.3	0
265	Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection. <i>Pharmaceuticals</i> , 2022, 15, 403.	1.7	2
266	Comparison of HIV DNA decay and immune recovery between early and chronic HIV-infected individuals 96 weeks after ART. <i>HIV Medicine</i> , 2022, 23, 6-13.	1.0	1
267	Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection. <i>Cell Discovery</i> , 2022, 8, 29.	3.1	18
268	Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection. <i>BMC Medical Ethics</i> , 2021, 22, 169.	1.0	2
269	Antiretroviral Initiation at $\geq 800$ CD4+ Cells/mm <sup>3</sup> Associated With Lower Human Immunodeficiency Virus Reservoir Size. <i>Clinical Infectious Diseases</i> , 2022, 75, 1781-1791.	2.9	4
272	Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection. <i>Journal of Virus Eradication</i> , 2022, 8, 100072.	0.3	2
273	Significance of initiating antiretroviral therapy in the early stage of HIV infection. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2022, 51, 373-379.	0.1	1
274	Design and validation of HIV peptide pools for detection of HIV-specific CD4+ and CD8+ T cells. <i>PLoS ONE</i> , 2022, 17, e0268370.	1.1	3
275	Bioactive Effects of Curcumin in Human Immunodeficiency Virus Infection Along with the Most Effective Isolation Techniques and Type of Nanoformulations. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 3619-3632.	3.3	20
276	Evaluation of antiretroviral therapy effect and prognosis between HIV-1 recent and long-term infection based on a rapid recent infection testing algorithm. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
278	Enteropathy and gut dysbiosis as obstacles to achieve immune recovery in undetectable people with HIV: a clinical view of evidence, successes, and projections. <i>Aids</i> , 2023, 37, 367-378.	1.0	1
279	Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, 213-218.	0.9	0
280	Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/ $\mu$ L on ART. <i>PLoS ONE</i> , 2023, 18, e0283648.	1.1	0
281	A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	4
283	Human Immunodeficiency Virus (HIV) Misdiagnosed as Pharyngitis. , 2023, , 319-328.		0